Medpace Holdings, Inc. $MEDP Shares Purchased by Farther Finance Advisors LLC

Key Points

• Farther Finance Advisors LLC has increased its stake in Medpace Holdings by 41.2% during the second quarter, owning 1,815 shares valued at approximately $570,000.
• Medpace's stock has experienced significant institutional interest, with a total of 77.98% of its shares owned by institutional investors and hedge funds.
• Medpace reported better-than-expected earnings per share (EPS) of $3.10 for the last quarter, exceeding analysts' estimates of $3.00, and highlighted a revenue increase of 14.2% compared to the previous year.

Farther Finance Advisors LLC increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 41.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,815 shares of the company's stock after acquiring an additional 530 shares during the quarter. Farther Finance Advisors LLC's holdings in Medpace were worth $570,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of MEDP. Mawer Investment Management Ltd. acquired a new position in shares of Medpace during the 1st quarter valued at about $212,131,000. Vulcan Value Partners LLC boosted its position in shares of Medpace by 221.6% during the 1st quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company's stock valued at $99,159,000 after acquiring an additional 224,578 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its position in shares of Medpace by 675.8% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company's stock valued at $37,009,000 after acquiring an additional 105,807 shares during the last quarter. Invesco Ltd. lifted its position in Medpace by 9.4% in the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock valued at $361,596,000 after buying an additional 102,015 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in Medpace by 41,658.9% in the first quarter. GAMMA Investing LLC now owns 93,540 shares of the company's stock valued at $28,501,000 after buying an additional 93,316 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $496.79 on Friday. The firm has a market capitalization of $13.95 billion, a PE ratio of 36.94, a price-to-earnings-growth ratio of 3.07 and a beta of 1.44. The firm's 50-day moving average is $464.83 and its two-hundred day moving average is $360.76. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $506.55.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. The company had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business's revenue for the quarter was up 14.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Activity at Medpace

In related news, Director Cornelius P. Mccarthy III sold 1,662 shares of the company's stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $465.04, for a total transaction of $772,896.48. Following the sale, the director directly owned 10,197 shares in the company, valued at approximately $4,742,012.88. This represents a 14.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO August J. Troendle sold 36,196 shares of the company's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $475.90, for a total transaction of $17,225,676.40. Following the sale, the chief executive officer owned 925,799 shares in the company, valued at $440,587,744.10. The trade was a 3.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 161,266 shares of company stock valued at $74,111,427. 20.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. UBS Group cut shares of Medpace from a "neutral" rating to a "sell" rating and upped their target price for the company from $300.00 to $305.00 in a research report on Tuesday, July 29th. Cowen cut shares of Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. Robert W. Baird upped their target price on shares of Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft upped their target price on shares of Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. Finally, Rothschild Redb cut shares of Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, September 3rd. Two research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Reduce" and an average price target of $422.27.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.